Bleeding Risk With Antiplatelets and Bruton's Tyrosine Kinase Inhibitors in Patients With Percutaneous Coronary Intervention.

ABSTRACT: Bruton's tyrosine kinase inhibitors (BTKi), known for their off-target antiplatelet effects and increased bleeding risk, have become more frequently used in patients with cancer with lymphoid malignancies. When encountering patients on BTKi who also require antiplatelet therapies, particularly dual-antiplatelet therapy that is a well-established treatment after percutaneous coronary intervention (PCI), the potential increase in bleeding risk raises concern. The development of new-generation BTKi with a higher selectivity, such as acalabrutinib and zanubrutinib, could be an answer to this conundrum, but bleeding still occurs. It is important that the interventional cardiologist becomes familiar with agents that could affect the management of antiplatelet therapy in patients treated with PCI

SUBMITTER: Mendez-Ruiz A 

PROVIDER: S-EPMC11308864 | biostudies-literature | 2023 May-Jun

REPOSITORIES: biostudies-literature